Lucid Diligence Brief - BioPharma

Lucid Diligence Brief: Gilead Sciences to acquire Ouro Medicines

Lucid Diligence Brief: Gilead Sciences to acquire Ouro Medicines Professional…


Lucid Diligence Brief - Tech

Lucid Diligence Brief: Fauna Bio obesity target designation with Lilly

Lucid Diligence Brief: Fauna Bio obesity target designation with Lilly…


Lucid Diligence Brief - BioPharma

Lucid Diligence Brief: Novartis to acquire Pikavation Therapeutics from Synnovation

Lucid Diligence Brief: Novartis to acquire Pikavation Therapeutics from…


Lucid Diligence Brief - BioPharma

Lucid Diligence Brief: Kupando adds €10 million to its Series A for Toll-like receptor assets

Lucid Diligence Brief: Kupando adds €10 million to its Series A for Toll-like…


Lucid Diligence Brief - BioPharma

Lucid Diligence Brief: Crossbow Therapeutics $77 million Series B for TCR-mimetics

Lucid Diligence Brief: Crossbow Therapeutics $77 million Series B for…


Lucid Diligence Brief - BioPharma

Lucid Diligence Brief: Samsung Bioepis and G2GBIO long-acting semaglutide collaboration

Lucid Diligence Brief: Samsung Bioepis and G2GBIO long-acting semaglutide…


Lucid Diligence Brief - Tech

Lucid Diligence Brief: Universal Health Services acquires Talkspace for $835 million

Lucid Diligence Brief: Universal Health Services acquires Talkspace for $835…


Lucid Diligence Brief - Tech

Lucid Diligence Brief: PRISM BioLab × Receptor.AI collaboration

Lucid Diligence Brief: PRISM BioLab × Receptor.AI collaboration Professional…


Lucid Diligence Brief - BioPharma

Lucid Diligence Brief: Enodia Therapeutics Kezar Sec61 deal

Lucid Diligence Brief: Enodia Therapeutics Kezar Sec61 deal Professional…


Privacy Preference Center